Skip to main content

BD Shares Rise on FDA OK for MRSA Test, Stock Upgrade

NEW YORK (GenomeWeb News) – Shares of Becton Dickinson rose nearly 4 percent today after the firm announced that the US Food and Drug Administration had cleared its GeneOhm StaphSR assay for identifying Staphylococcus aureus and methicillin-resistant S. aureus from patients with positive blood cultures in around two hours.
 
BD’s shares hit an all-time high of $88.17 in early trade before settling back to close at $86.78, up 3.8 percent for the day, on the New York Stock Exchange.
 
According to BD, the StaphSR assay is the first molecular-based test to identify and distinguish SA and MRSA infections, thus enabling physicians to make earlier diagnoses of these infections and potentially save lives and significantly reduce healthcare costs.
 
BD already sells an earlier-generation of the test, the GeneOhm MRSA assay, which it gained through its 2006 acquisition of GeneOhm Sciences for $230 million and an extra $25 million in incentives.
 
BD’s tests compete with a molecular MRSA assay sold by Cepheid, which was cleared for marketing by the FDA last April. Cepheid claims its test can be performed on its GeneXpert system and can identify MRSA infection in just over one hour.
 
Cepheid officials recently said that the firm intends to launch a combination MRSA/SA test for skin and soft tissue infections in 2008.
 
While BD's shares rose, Cepheid's shares closed down 2.6 percent on the Nasdaq.
 
In addition to the FDA clearance, BD’s shares were boosted by investment bank JPMorgan upgrading the company’s stock to “overweight” from “neutral” and raising its fiscal 2008 profit estimate for the firm to $4.36 per share from $4.32.
 
JPMorgan analyst Michael Weinstein said in a research note that BD is “well positioned in some of today’s more attractive MedTech segments, including both safety-infection control and molecular diagnostics.”
 
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.